Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?  

In this situation, it is helpful to review the eligibility and exclusion criteria from the VISION protocol directly. These can be found at NCT03511664 (Sartor et al., PMID 34161051). Many of these patients have been heavily pretreated, including prior taxane therapy, so my main concern is that they ...

I completely agree with Dr. Anscher’s response. Dr Kendra Harris taught me not mess with the platelets, so I watch these closest. The Grade 5 events in the VISION trial were bleeding related. Not strict exclusion criteria but food for thought: PS is important as patients should be able to do...